Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart, Anlotinib, and Chemotherapy for First-Line Treatment of LCNEC and EP-NEC
NCT07510594Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in large cell neuroendocrine carcinoma (LCNEC) and extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 12 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
large cell neuroendocrine carcinoma (LCNEC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07510594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510594.